^abcMoret C, Grimaldi B, Massot O, Fillion G (April 2003). "The role and therapeutic potential of 5-HT-moduline in psychiatry".Seminars in Clinical Neuropsychiatry.8 (2) ascnp50013:137–146.doi:10.1053/scnp.2003.50013.PMID12728412.
^abcdefFillion G (September 2000). "Potential of 5-HT-moduline as a drug target for affective disorders".Current Opinion in Investigational Drugs.1 (1):104–109.PMID11249585.
^abFillion G, Rousselle JC, Massot O, Zifa E, Fillion MP, Prudhomme N (1996). "A new peptide, 5-HT-moduline, isolated and purified from mammalian brain specifically interacts with 5-HT1B/1D receptors".Behavioural Brain Research.73 (1–2):313–317.doi:10.1016/0166-4328(96)00120-9.PMID8788526.
^Massot O, Rousselle JC, Fillion MP, Grimaldi B, Cloëz-Tayarani I, Fugelli A, et al. (October 1996). "5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors".Molecular Pharmacology.50 (4):752–762.doi:10.1016/S0026-895X(25)09375-7.PMID8863819.
^Seguin L, Seznec JC, Fillion G (March 1997). "The endogenous cerebral tetrapeptide 5-HT-moduline reduces in vivo the functional activity of central 5-HT1B receptors in the rat".Neuroscience Research.27 (3):277–280.doi:10.1016/s0168-0102(96)01150-9.PMID9129186.
^Rousselle JC, Plantefol M, Fillion MP, Massot O, Pauwels PJ, Fillion G (September 1998). "Specific interaction of 5-HT-moduline with human 5-HT1b as well as 5-HT1d receptors expressed in transfected cultured cells".Naunyn-Schmiedeberg's Archives of Pharmacology.358 (3):279–286.doi:10.1007/pl00005254.PMID9774213.
^Grimaldi B, Fillion MP, Bonnin A, Rousselle JC, Massot O, Fillion G (August 1997). "Immunocytochemical localization of neurons expressing 5-HT-moduline in the mouse brain".Neuropharmacology.36 (8):1079–1087.doi:10.1016/s0028-3908(97)00099-3.PMID9294973.
^Massot O, Rousselle JC, Grimaldi B, Cloëz-Tayarani I, Fillion MP, Plantefol M, et al. (December 1998). "Molecular, cellular and physiological characteristics of 5-HT-moduline, a novel endogenous modulator of 5-HT1B receptor subtype".Annals of the New York Academy of Sciences.861:174–182.doi:10.1111/j.1749-6632.1998.tb10189.x.PMID9928255.
^Bentué-Ferrer D, Reymann JM, Rousselle JC, Massot O, Bourin M, Allain H, et al. (October 1998). "5-HT-moduline, a 5-HT(1B/1D) receptor endogenous modulator, interacts with dopamine release measured in vivo by microdialysis".European Journal of Pharmacology.358 (2):129–137.doi:10.1016/s0014-2999(98)00586-x.PMID9808261.
^Bourin M, Hascoët M (February 2001). "Drug mechanisms in anxiety".Current Opinion in Investigational Drugs.2 (2):259–265.PMID11816841.
^Grimaldi B, Bonnin A, Fillion MP, Prudhomme N, Fillion G (1999). "5-Hydroxytryptamine-moduline: a novel endogenous peptide involved in the control of anxiety".Neuroscience.93 (4):1223–1225.doi:10.1016/s0306-4522(99)00322-x.PMID10501445.
^Clénet F, Hascoët M, Fillion G, Galons H, Bourin M (December 2004). "Anxiolytic profile of HG1, a 5-HT-moduline antagonist, in three mouse models of anxiety".European Neuropsychopharmacology.14 (6):449–456.doi:10.1016/j.euroneuro.2003.12.004.PMID15589384.
^Clénet F, Hascoët M, Fillion G, Galons H, Bourin M (March 2005). "Role of GABA-ergic and serotonergic systems in the anxiolytic-like mechanism of action of a 5-HT-moduline antagonist in the mouse elevated plus maze".Behavioural Brain Research.158 (2):339–348.doi:10.1016/j.bbr.2004.09.015.PMID15698901.
^Plantefol M, Rousselle JC, Massot O, Bernardi E, Schoofs AR, Pourrias B, et al. (December 1999). "Structural requirements of 5-hydroxytryptamine-moduline analogues to interact with the 5-hydroxytryptamine1B receptor".Journal of Neurochemistry.73 (6):2617–2620.doi:10.1046/j.1471-4159.1999.0732617.x.PMID10582626.
.svg)
